实用肝脏病杂志 ›› 2021, Vol. 24 ›› Issue (4): 581-584.doi: 10.3969/j.issn.1672-5069.2021.04.032

• 肝血管瘤 • 上一篇    下一篇

平阳霉素联合超化碘油混悬液经动脉介入栓塞治疗肝血管瘤患者中远期疗效研究*

唐文涛, 黄会, 蔡婵娟   

  1. 431700 湖北省天门市第一人民医院介入科(唐文涛,蔡婵娟);华中科技大学同济医学院附属梨园医院呼吸与危重症医学科(黄会)
  • 收稿日期:2020-10-29 发布日期:2021-07-13
  • 作者简介:唐文涛,男,35岁,大学本科,主治医师。E-mail:tangwentao6688@163.com
  • 基金资助:
    *天门市科研计划项目(编号:2018T02007)

Long-term curative effects of transarterial embolization with pingyangmycin-lipiodol suspension in the treatment of patients with hepatic hemangioma

Tang Wentao, Huang Hui, Cai Chanjuan   

  1. Department of Radiologic Intervention, First PeoPLS's Hospital,Tianmen 431700,Hubei Province,China
  • Received:2020-10-29 Published:2021-07-13

摘要: 目的 探讨采用平阳霉素-超化碘油混悬液(PLS)经动脉介入栓塞治疗肝血管瘤(HH)患者的中远期疗效。方法 2012年2月~2016年12月我院收治的56例肝血管瘤患者,其中28例接受PLS动脉介入栓塞治疗(观察组),另28例行博来霉素-超化碘油混悬液动脉介入栓塞治疗(对照组),随访36个月,使用CT检查测量瘤体大小的变化。结果 在治疗后6个月,观察组总有效率显著高于对照组(89.3%对64.3%,P<0.05),在治疗后36个月,两组临床疗效比较,差异无统计学意义(96.4%对92.9%,P>0.05);两组并发症总发生率比较,差异无统计学意义(25.0%对14.3%,P>0.05);在治疗后6个月、12个月和24个月,观察组瘤体直径分别为(7.3±0.5)cm、(5.6±0.7)cm和(3.4±1.4)cm,均显著小于对照组【分别为(8.1±0.7)cm、(7.3±1.2)cm和(4.5±0.7),P<0.05】,而在治疗后第36个月,两组瘤体直径无显著性差异【(1.9±0.3)cm对(2.4±0.5)cm,P>0.05】。结论 采用PLS或博来霉素-超化碘油介入栓塞治疗肝血管瘤患者的中远期效果相当,但治疗后早期,采用PLS介入栓塞治疗的疗效可能更好,都需要随访观察。

关键词: 肝血管瘤, 平阳霉素-超化碘油混悬液, 博来霉素-超化碘油混悬液, 经动脉介入栓塞, 治疗

Abstract: Objective The aim of this study was to investigate the long-term curative effects of transarterial embolization with pingyangmycin-lipiodol suspension (PLS) in the treatment of patients with hepatic hemangioma (HH). Methods A total of 56 patients with HH were enrolled in our hospital between February 2012 and December 2016, and were divided into two groups. 28 patients with HH were treated by transarterial embolization with PLS, and another 28 were with bleomycin-lipiodol suspension (BLS), and all patients were followed-up for 36 months. The clinical curative effects, incidences of postoperative complications and reduction of maximum tumor diameter were recorded in the two groups. Results At the end of six month after treatment, the total effective rate in PLS-treated patients was significantly higher than that in BLS-treated patients (89.3% vs. 64.3%, P<0.05), and at the end of thirty-six month after treatment, there was no significant difference as respect to the effective rates in the two groups (96.4% vs. 92.9%, P>0.05); there was no significant difference in total complications after operation in the two groups (25.0% vs. 14.3%, P>0.05); at the end of six month, twelve month and twenty-four month after treatment, the tumor diameters in PLS-treated patients were (7.3±0.5)cm,(5.6±0.7)cm and (3.4±1.4)cm, all significantly smaller than [(8.1±0.7)cm,(7.3±1.2)cm and (4.5±0.7), respectively, P<0.05] in BLS-treated patients, while at the end of thirty-six month, the tumor diameters in the two groups were not significantly different [(1.9±0.3)cm vs. (2.4±0.5)cm, P>0.05]. Conclusion PLS and BLS by transarterial embolization both have comparable long-term effects in treatment of patients with HH, and the PLS seems work early, which needs further clinical observation.

Key words: Hepatic hemangioma, Pingyangmycin-lipiodol suspension, Bleomycin-lipiodol suspension, Transarterial embolization, Therapy